Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 known ✓ | O00206 | 1/20 | 0.52 |
| ▸ | FGF1 known ✓ | P05230 | 1/20 | 0.43 |
| ▸ | SELP | P16109 | 8/20 | 0.57 |
| ▸ | SELL | P14151 | 2/20 | 0.57 |
| ▸ | VEGFA | P15692 | 5/20 | 0.52 |
| ▸ | FGF2 | P09038 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8335408 | 0.91 | SELP (0.51) | SELPSELLTLR4VEGFAFGF1 | |
| SCHEMBL8335411 | 0.91 | SELP (0.51) | SELPSELLTLR4VEGFAFGF1 | |
| SCHEMBL258055 | 0.90 | TLR4 (0.53) | SELPSELLTLR4VEGFA | |
| SCHEMBL8333368 | 0.89 | SELP (0.66) | SELPSELLVEGFAFGF1FGF2 | |
| SCHEMBL8333154 | 0.87 | SELP (0.61) | SELPSELLVEGFAFGF1FGF2 | |
| SCHEMBL8329861 | 0.81 | HPSE (0.67) | SELPSELLVEGFAFGF1FGF2 | |
| SCHEMBL8333751 | 0.80 | SELL (0.59) | SELPSELLTLR4 | |
| SCHEMBL1573005 | 0.80 | SELL (0.59) | SELPSELLTLR4 | |
| SCHEMBL15618387 | 0.80 | SELL (0.59) | SELPSELLTLR4 | |
| SCHEMBL15618579 | 0.80 | SELL (0.59) | SELPSELLTLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968607-B2 | Cosmetics 1-isostearylglycerol-3-Sulfate Sodium Salt, used for constriction of keratinocytes; aging resistance | KOA CORPORATION (JP) | 2011-06-28 | — | — | US | disclosed |
| EP-1325737-B1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | KAO CORP (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | KAO CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | KAO CORPORATION (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1325737-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | Kao Corporation (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | CUTA, DSG1, OGA | TLR4 1588/4885FGF1 148/4885SELP 1887/4885 |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | DSG1, CUTA, OGA | TLR4 1772/4885FGF1 466/4885SELP 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.